Literature DB >> 16036395

MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia.

Jenny E Myers1, Shaila J Merchant, Maureen Macleod, Gary J Mires, Philip N Baker, Sandra T Davidge.   

Abstract

OBJECTIVE: To determine levels of matrix metalloproteinase (MMP)-2 and MMP-9, and the tissue inhibitors of metalloproteinases (TIMP)-1 and TIMP-2 in the plasma of women destined to develop preeclampsia prior to the onset of clinical disease. STUDY
DESIGN: Plasma samples were taken from women whose pregnancies were subsequently complicated by preeclampsia and from normal pregnant women at 22 and 26 weeks and at delivery or diagnosis. Following equal protein loading, MMP-2 and 9 and TIMP-1 and 2 were quantified using zymography and Western blot analysis, respectively.
RESULTS: Plasma MMP-2 levels were significantly elevated at 22 weeks (p = 0.02) and at diagnosis (p = 0.003) in the preeclampsia group, but there was no difference at 26 weeks. TIMP-1 levels were significantly reduced in the preeclampsia group at 26 weeks (p = 0.0002), but TIMP-2 levels were not quantifiable.
CONCLUSION: At all three gestational time points an imbalance in the MMP-2:TIMP-1 ratio was found in patients who subsequently developed preeclampsia. We speculate that increased net MMP-2 activity may contribute to the endothelial dysfunction that is central to the pathophysiology of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16036395     DOI: 10.1081/PRG-200059836

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  34 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Placental membrane-type metalloproteinases (MT-MMPs): Key players in pregnancy.

Authors:  Alejandro Majali-Martinez; Ursula Hiden; Nassim Ghaffari-Tabrizi-Wizsy; Uwe Lang; Gernot Desoye; Martina Dieber-Rotheneder
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

Review 3.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 4.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

5.  Trophoblast survival signaling during human placentation requires HSP70 activation of MMP2-mediated HBEGF shedding.

Authors:  Chandni V Jain; Philip Jessmon; Charbel T Barrak; Alan D Bolnick; Brian A Kilburn; Michael Hertz; D Randall Armant
Journal:  Cell Death Differ       Date:  2017-07-21       Impact factor: 15.828

6.  Regulation of trophoblast invasion: the role of matrix metalloproteinases.

Authors:  Jia-Yu Zhu; Zhan-Jun Pang; Yan-Hong Yu
Journal:  Rev Obstet Gynecol       Date:  2012

7.  Circulating levels of matrix proteases and their inhibitors in pregnant women with and without a history of recurrent pregnancy loss.

Authors:  Dilly O C Anumba; Saad El Gelany; Sarah L Elliott; Tin C Li
Journal:  Reprod Biol Endocrinol       Date:  2010-06-16       Impact factor: 5.211

8.  Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy.

Authors:  Martina Montagnana; Giuseppe Lippi; Alessandro Albiero; Silvia Scevarolli; Gian Luca Salvagno; Massimo Franchi; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 9.  Matrix metalloproteinases as drug targets in preeclampsia.

Authors:  Ana C T Palei; Joey P Granger; Jose E Tanus-Santos
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

10.  Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia.

Authors:  Michal Lavee; Shlomit Goldman; Etty Daniel-Spiegel; Eliezer Shalev
Journal:  Reprod Biol Endocrinol       Date:  2009-08-23       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.